Ocifisertib(CFI-400945 free base) NEW
Price | $38 | $88 | $143 |
Package | 1mg | 5mg | 10mg |
Min. Order: | |
Supply Ability: | 10g |
Update Time: | 2024-11-18 |
Product Details
Product Name: Ocifisertib(CFI-400945 free base) | CAS No.: 1338806-73-7 |
Purity: 98.53% | Supply Ability: 10g |
Release date: 2024/11/18 |
Product Introduction
Bioactivity
Name | Ocifisertib(CFI-400945 free base) |
Description | Ocifisertib (CFI-400945 free base) is a potent, selective and orally active inhibitor of polo-like kinase 4 (PLK4; Ki value 0.26 nM; IC50 value 2.8 nM). |
In vitro | METHODS: HCT116 cells with FLAG-tagged full-length PLK4 were treated with Ocifisertib (CFI-400945 free base) for 4 hours, and the lysates were analyzed by immunoblotting. RESULTS In cells overexpressing PLK4, Ocifisertib inhibited PLK4 autophosphorylation at serine 305 with an EC50 value of 12.3 nM.[1] |
In vivo | METHODS: PK analysis was performed in mice treated with ocifisertib (CFI-400945 free base) (3.75-104 mg/kg, oral). RESULTS CFI-400945 was rapidly absorbed after oral administration, reaching maximum plasma concentrations (Cmax) of 0.25–11.68 μg/mL; the elimination half-life was 3.7-4.2 hours at 3.75-26 mg/kg, but was prolonged with increasing doses (5.4 and 6.9 hours at 52 and 104 mg/kg, respectively). [1] |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | Ethanol : 100 mg/mL (187.04 mM) H2O : Insoluble DMSO : 100 mg/mL (187.04 mM), Heating to 50℃ is recommended. |
Keywords | CFI400945 free base | CFI-400945 | Ocifisertib | CFI-400945 free base | CFI 400945 free base | CFI400945 | CFI 400945 |
Inhibitors Related | Onvansertib | Plogosertib | T521 | (E/Z)-Rigosertib sodium | SBE13 Hydrochloride | Pyridoxine | Rigosertib sodium | 3MB-PP1 | Ro3280 | Poloxin-2 | BI 2536 | GSK461364 |
Related Compound Libraries | 經(jīng)典已知活性庫 | 激酶抑制劑庫 | 藥物功能重定位化合物庫 | 抑制劑庫 | 口服活性化合物庫 | 臨床期小分子藥物庫 | 已知活性化合物庫 | 細胞周期化合物庫 | 抗癌化合物庫 | 抗癌活性化合物庫 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
Product name | Price | Suppliers | Update time | |
---|---|---|---|---|
$0.00/1kg |
VIP6Y
|
Zison Pharmaceutical (Shandong) Co., Ltd.
|
2024-05-24 | |
$102.00/1kg |
VIP2Y
|
Wuhan Quanjinci New Material Co.,Ltd.
|
2023-10-24 | |
$1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY